Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.

"We don't need to spend another $140 million to find out how to retain people in care," activist David Barr writes. "We need to invest in the kinds of services people need so that they can use treatment easily and effectively."

Atripla may be just as effective when taken every other day; poor antiretroviral prescription fill rates after hospitalization; U.S. progress against UNAIDS targets; hepatitis C transmission clustering in France.

"Placing more attention on meeting the sexual health and holistic wellness needs of gay men affected by sexualized substance use is critical," writes the associate director of Ontario's Gay Men's Sexual Health Alliance.

Although the move means that more Britons might be able to access free PrEP, this study is also controversial for being seen as a way to delay full government approval.

A cellphone attachment that detects HIV RNA; HIV-2 does indeed often progress to AIDS; CD4 count declines and incident hepatitis C coinfection; the global demographics of non-Hodgkin lymphoma.

PrEP access appears far from equal in the U.S.; HIV treatment and viral suppression disparities in Europe; how today’s hepatitis C treatments affect mortality; sex-based differences in cognitive impairment.

A poster presented at the annual IDWeek conference in San Francisco illustrated the lag between the World Health Organization's recommendations and PrEP uptake in an urban setting in Jamaica.

On Sept. 24, the first widespread inquiry into how thousands of people in the United Kingdom received contaminated blood in the 1970s and 1980s began with a preliminary hearing and a commemoration event dedicated to the victims.

In a study of more than 1,400 women living with HIV, nearly 30% did not achieve viral suppression and some groups of women had greater challenges with adherence and staying in care.